DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.

Information source: Pfizer
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Generalized Anxiety Disorder

Intervention: Pregablin (Drug); Placebo (Other)

Phase: Phase 3

Status: Recruiting

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Overall contact:
Pfizer CT.gov Call Center, Phone: 1-800-718-1021

Summary

GAD subjects maintained on a stable dose of alprazolam for at least four weeks who meet eligibility criteria will be randomized to receive pregabalin vs matching placebo while simultaneously tapering off of alprazolam over 6 weeks. Subjects return weekly for assessment of safety/tolerability of pregablin vs placebo as well as for assessment of anxiety and benzodiazepine withdrawal symptoms. Subjects sucessfully able to discontinue alprazolam, will continue 6 weeks of treatment with pregabalin vs placebo (free of benzodiazepine use). The efficacy and safety of pregablin vs placebo for anxiety symptoms and ability to discontinue/remain free of alprazolam will be compared among pregablin and placebo treated groups. Hypothesis is that a greater proportion of subjects will be successful in discontinuing and remaining free from benzodiazepines who were treated with pregabalin as compared to subjects treated with placebo.

Clinical Details

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Pregabalin in Subjects With Generalized Anxiety Disorder (GAD) Switching From Benzodiazepine Therapy.

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study

Primary outcome:

Negative urine benzodiazepine/psychoactive toxicology assay (done at each visit of the Alprazolam-Free Phase of Double-Blind Treatment) and negative serum benzodiazepine/alcohol assay (done at endpoint).

Negative benzodiazepine use defined as negative labs for benzodiazepines as well not requiring use of 'rescue' alprazolam packet between visits

Efficacy/Safety: Following taper and discontinuation from stable benzodiazepine treatment,the proportion of subjects treated with pregabalin who remain 6 weeks free from benzodiazepine use compared to subjects treated with placebo.

Secondary outcome:

Mean change between 'randomization/baseline' score of Clinical Global Impression Severity (CGI-S) and weekly scores of CGI-S.

Proportion of subjects with > 6 point increase in PWC scores compared to baseline or compared to a previous week in the 6 week benzodiazepine free period.

Proportion of subjects with > 5 new PWC symptoms between weekly visits during the benzodiazepine free 6 week period or between a weekly visit and baseline visit.

Amount of time 'relapse free' among treatment groups during 6 week 'benzodiazepine free'phase (Relapse free-defined as negative labs for benzodiazepines and not requiring more than allowed rescue benzodiazepine medication between visits)

Mean 'Patient Global Impression-Improvement' (PGI-I) score at each visit.

Mean Clinician Global Impression-Improvement (CGI-I) score at each visit.

Time until first subject needs to take "rescue medication"

Mean change in weekly 'Physician Withdrawal Checklist' (PWC) scores compared to randomization /baseline

Mean change from randomization /baseline to endpoint in 'Digit Symbol Substitution Test'(DSST) scores

Mean change in weekly anxiety scores compared to baseline (measured by Hamilton Anxiety Scale or HAM-A)

Time until subject discontinuation (inability to tolerate benzodiazepine taper or free state)

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Provide written informed consent

- 18-65 years old

- male and female

- A primary lifetime diagnosis of DSM-IV-TR (2000) GAD (Diagnostic and Statistical

Manual of Mental Disorders, Fourth Edition)

Exclusion Criteria:

- Pregnant or lactating women

- History of non-response to alprazolam, other benzodiazepines, gabapentine or

pregabalin given for the treatment of anxiety as indicated by a (screening or baseline) Hamilton Anxiety Scale (HAM-A) score > 18

Locations and Contacts

Pfizer CT.gov Call Center, Phone: 1-800-718-1021

Pfizer Investigational Site, Plzen 301 00, Czech Republic; Completed

Pfizer Investigational Site, Praha 7 170 00, Czech Republic; Completed

Pfizer Investigational Site, Praha-Bubenec 170 00, Czech Republic; Completed

Pfizer Investigational Site, Praha 6 163 00, Czech Republic; Recruiting

Pfizer Investigational Site, Praha 10 - Hostivar 102 00, Czech Republic; Completed

Pfizer Investigational Site, Elancourt 78990, France; Completed

Pfizer Investigational Site, Nantes-Orvault 44700, France; Completed

Pfizer Investigational Site, ARCACHON 33120, France; Completed

Pfizer Investigational Site, Caen 14000, France; Completed

Pfizer Investigational Site, Guatemala, Guatemala; Active, not recruiting

Pfizer Investigational Site, 20157 Milano 20157, Italy; Completed

Pfizer Investigational Site, L'Aquila 67100, Italy; Active, not recruiting

Pfizer Investigational Site, Mexico D.F. 03740, Mexico; Completed

Pfizer Investigational Site, San Luis Potosi 78216, Mexico; Active, not recruiting

Pfizer Investigational Site, BARCELONA 08036, Spain; Active, not recruiting

Pfizer Investigational Site, BARCELONA 08025, Spain; Completed

Pfizer Investigational Site, ZAMORA 49021, Spain; Completed

Pfizer Investigational Site, LANGREO, ASTURIAS 33900, Spain; Completed

Pfizer Investigational Site, Paris, Cedex 12 75571, France; Completed

Pfizer Investigational Site, Tepic, Nayarit 63000, Mexico; Active, not recruiting

Pfizer Investigational Site, San Pedro de Montes de Oca, San José 00, Costa Rica; Completed

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: September 2006
Ending date: September 2008
Last updated: October 9, 2008

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012